BTIG Research upgraded shares of EXACT Sciences (NASDAQ:EXAS) from a neutral rating to a buy rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports.
Several other equities analysts have also commented on the stock. Bank of America set a $67.00 price objective on shares of EXACT Sciences and gave the company a buy rating in a research report on Monday, January 8th. Benchmark set a $65.00 price objective on shares of EXACT Sciences and gave the company a buy rating in a research report on Wednesday, January 17th. William Blair reiterated a buy rating on shares of EXACT Sciences in a research report on Tuesday, January 2nd. Zacks Investment Research lowered shares of EXACT Sciences from a buy rating to a hold rating in a research report on Friday, January 19th. Finally, BidaskClub lowered shares of EXACT Sciences from a buy rating to a hold rating in a research report on Tuesday, December 12th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $52.84.
EXAS stock opened at $37.84 on Tuesday. EXACT Sciences has a 52 week low of $22.30 and a 52 week high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.15 and a quick ratio of 6.77. The firm has a market cap of $4,898.13, a price-to-earnings ratio of -38.22 and a beta of 0.87.
In other news, insider Graham Peter Lidgard sold 39,884 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $43.10, for a total value of $1,719,000.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP D Scott Coward sold 2,122 shares of the firm’s stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $40.12, for a total transaction of $85,134.64. The disclosure for this sale can be found here. Insiders sold a total of 449,995 shares of company stock valued at $21,876,323 in the last 90 days. Company insiders own 4.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in EXAS. Carillon Tower Advisers Inc. bought a new stake in shares of EXACT Sciences in the 4th quarter worth about $66,280,000. Victory Capital Management Inc. lifted its holdings in EXACT Sciences by 82.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company’s stock valued at $62,499,000 after buying an additional 539,160 shares in the last quarter. Emerald Advisers Inc. PA bought a new stake in EXACT Sciences during the 4th quarter valued at about $21,813,000. Jennison Associates LLC lifted its holdings in EXACT Sciences by 258.9% during the 4th quarter. Jennison Associates LLC now owns 518,589 shares of the medical research company’s stock valued at $27,247,000 after buying an additional 374,078 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in EXACT Sciences by 41.6% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 723,738 shares of the medical research company’s stock valued at $34,103,000 after buying an additional 212,697 shares in the last quarter. Hedge funds and other institutional investors own 82.02% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “EXACT Sciences (EXAS) Raised to Buy at BTIG Research” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3337940/exact-sciences-exas-raised-to-buy-at-btig-research.html.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.